Skip to main content

Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

  • Poster presentation
  • Open access
  • Published:

Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy

Adoptive T cell therapy can mediate durable regression of cancer [1]. While pre-existing anti-tumor responses can only be cultured from a minority of cancer patients [2], T cells specific for a wide variety of tumor antigens can be generated by stimulation of naive precursor cells with tumor antigen [3]. This culture process relies on autologous antigen presenting cells and feeder cells, which are complex biologics that must be generated for each individual patient [4], significantly increasing the cost and complexity of adoptive immunotherapy.

To quickly generate large numbers of functional tumor-specific T cells from naïve T cell precursors, we developed a T cell Enrichment+Expansion strategy using paramagnetic, nanoscale artificial Antigen Presenting Cells (nano-aAPC), which are capable of enriching rare tumor-specific T cells in a magnetic column and activating them. We generated up to 150,000 total Trp2-specific cells in only one week from 10 million polyclonal CD8 lymphocytes containing approximately 10 precursor cells [5]. Similar results were obtained for other tumor and model antigens, including the human tumor antigens A2-NY-ESO1 and A2-MART1. We further demonstrate that removing irrelevant bystander cells by enrichment confers a significant survival and proliferation advantage to tumor-specific T cells both during in vitro culture and after adoptive transfer in vivo. Streamlining the generation of large numbers of high-frequency tumor-specific T cells in a cost effective, reproducible fashion through Enrichment+Expansion could be a powerful addition to autologous tumor immunotherapy protocols.


  1. Restifo NP, Dudley ME, Rosenberg Sa: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012, 12: 269-81. 10.1038/nri3191.

    Article  CAS  PubMed  Google Scholar 

  2. Dudley ME, Rosenberg Sa: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003, 3: 666-75. 10.1038/nrc1167.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Yee C: The use of endogenous T cells for adoptive transfer. Immunol. Rev. 2014, 257: 250-63. 10.1111/imr.12134.

    Article  CAS  PubMed  Google Scholar 

  4. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Trevess AJ, Shalmon B, Zippel D, Markel G, Shapira-frommer R, Schachter J, MJBJ : Establishment and Large-scale Expansion of Minimally Adoptive Transfer Therapy. J Immunother. 2011, 34: 212-220.

    Article  PubMed  Google Scholar 

  5. Jenkins MK, Chu HH, McLachlan JB, JL : Moon, On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands. Annu Rev Immunol. 2010, 28: 275-94. 10.1146/annurev-immunol-030409-101253.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perica, K., Bieler, J., Schuetz, C. et al. Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy. j. immunotherapy cancer 2 (Suppl 3), P34 (2014).

Download citation

  • Published:

  • DOI: